Viatris (VTRS) Net Equity Issued and Repurchased (2022 - 2026)
Viatris' (VTRS) quarterly Net Equity Issued and Repurchased came in at $500000.0 in Q1 2026, down 16.67% year-on-year from $600000.0 in Q1 2025, and down 16.67% quarter-over-quarter from $600000.0 in Q4 2025.
Viatris (VTRS) Net Equity Issued and Repurchased (2022 - 2026) Analysis & Trends
Viatris' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at $500000.0 for Q1 2026.
- On a quarterly basis, Net Equity Issued and Repurchased fell 16.67% year-over-year to $500000.0 in Q1 2026; TTM through Mar 2026 was $2.5 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $2.6 million, up 4.0% from the prior year.
- Net Equity Issued and Repurchased eased to $500000.0 in Q1 2026 per VTRS's latest filing, from $600000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $1.8 million in Q3 2022 and bottomed at $500000.0 in Q1 2026.
- The 5-year median for Net Equity Issued and Repurchased is $700000.0 (2022), against an average of $750000.0.
- Across the five-year window, Net Equity Issued and Repurchased sank 55.56% in 2023 and climbed 16.67% in 2025, its largest moves.
- Year by year, Net Equity Issued and Repurchased stood at $800000.0 in 2022, then decreased by 25.0% to $600000.0 in 2023, then changed by 0.0% to $600000.0 in 2024, then changed by 0.0% to $600000.0 in 2025, then retreated by 16.67% to $500000.0 in 2026.
- Per Business Quant, the three latest VTRS Net Equity Issued and Repurchased figures stand at $500000.0 (Q1 2026), $600000.0 (Q4 2025), and $700000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 500,000.00 |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 23.60 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 500,000.00 |
| Mar 31, 2026 | 500,000.00 |
| Dec 31, 2025 | 600,000.00 |
| Dec 31, 2025 | 600,000.00 |
| Sep 30, 2025 | 700,000.00 |
| Sep 30, 2025 | 700,000.00 |
| Jun 30, 2025 | 700,000.00 |
| Jun 30, 2025 | 700,000.00 |
| Mar 31, 2025 | 600,000.00 |
| Mar 31, 2025 | 600,000.00 |
| Dec 31, 2024 | 600,000.00 |
| Dec 31, 2024 | 600,000.00 |
| Sep 30, 2024 | 600,000.00 |
| Sep 30, 2024 | 600,000.00 |
| Jun 30, 2024 | 700,000.00 |
| Jun 30, 2024 | 700,000.00 |
| Mar 31, 2024 | 600,000.00 |
| Mar 31, 2024 | 600,000.00 |
| Dec 31, 2023 | 600,000.00 |
| Dec 31, 2023 | 600,000.00 |